NiceR - Novel immunoglobulin cleaving enzymes for Repeat dosing

Hansa Medical is developing completely new IgG degrading enzymes based on experience from imlifidase and similar molecules. The aim of the development is to create novel IgG inactivating drugs that can be used for repeated dosing in autoimmune conditions where patients benefit from more than one dose of an IgG-modulating enzyme. Hansa Medical has filed patent applications covering these molecules.

A broad repertoire of novel immunoglobulin cysteine endopeptidases has been developed and patented. As of November 2018, the development program is being prepared for pre-clinical development, including CMC development and toxicology studies.